I-Xolair (i-Omalizumab): unyango lwe-Asthma ye-Allergic

Ukhuseleko, nemiphumo emibi, kunye nokunye

I-Xolair (i-omalizumab) yicirisi ejoyiweyo esetyenziselwa ukunyanga ngokumalunga ne- asthma . Ingasetyenziselwa abantu abantu abaneminyaka engama-12 nangaphezulu ababenaso isifo se-asthma naphezu kweempawu zonyango zesifo se-asthma , ezifana ne- steroids e-inhaled .

Izifungo zinikezelwa kwiofisi yegqirha nganye iiveki ezimbini ukuya kwezine kuxhomekeke kumlinganiselo womntu kunye ne-antigenic antibody (IgE).

(Khangela ukubona ukuba i-asthma yakho ilawulwa ngokuthatha uvavanyo lwe-asthma.)

Yiyiphi i-Xolair?

I-Xolair yi-anti-IgE e-anti-IgE ephikisana ne-IgE egazini, evumela umzimba ukuba uyisuse. Isilwanyana siphuculelwa kwiigundane kwaye ngoko iqulethe iprotheni ye mouse emalunga ne-5 ekhulwini (ayibonakali ukuba ukungabikho komzimba kwiprotheni ye mouse kukubangela iingxaki kubantu abafumana i-Xolair).

Oku kuvimbela i-IgE ukuba ixhomekeke kumaseli amancinci kwaye ibophe kwiimpawu, ezigqityiweyo ekugqibeleni i- histamine nezinye iikhemikhali. Zizo ezo makhemikhali ezibangele ukwanda kwesifo se-asthma kunye nezinye iimpawu zokugula.

Isilwayo siboniswe ukunciphisa ukuhlaselwa kwe-asthma, ukuphucula umgangatho wobomi bonke abantu abane-asthma, nokunciphisa i- corticosteroids efunekayo. Ngokuqhelekileyo, kungathatha iinyanga ezimbalwa zeejovyi ze-Xolair ukuba ziqale ukusebenza. Kwaye amayeza angabiza kakhulu.

I-Xolair ayilona unyango lweempawu ze-asthma ziya kulindeleka ukuba zibuhlungu ngakumbi emva kweenyanga ezimbalwa emva kokuba unyango lwe-Xolair lugqitywe.

Ingathatha i-Xolair ingozi?

I-Xolair ngoku ine-"ibhokisi emnyama" isilumkiso, esilumkiso sokuqapha esinikezelwa ngamachiza yi-US Food and Drug Administration (FDA). Esi si lumkiso siphumelele ngenxa yeengxelo zabantu abafumana i- anaphylaxis (ukusabela okuthe tye) emva kokufumana i-Xolair.

Nangona kungekho zi ingxelo ze-anaphylaxis ebulalayo ngenxa ye-Xolair, ezinye iimeko ziye zazingqongqo kwaye zisenokusongela ubomi. Ngesi sizathu, i-FDA idinga ukuba abantu abafumana i-Xolair babekwe esweni kwiofisi yabo ngogqirha ngexesha elithile emva kweeyunithi zabo. (Inani langempela lexesha limiswe ngugqirha.)

Abantu abafumana i-Xolair kufuneka bajonge iimpawu ezilandelayo ze-anaphylaxis, enokuthi ifike kwiiyure ezingama-24 (okanye ngaphezulu) emva kwe-injection:

Ngaba kukho naziphi na ezi zibonakaliso, kubalulekile ukuxelela ugqirha wakho ngokukhawuleza. Amagqirha amaninzi anika izigulane ezine-injection epinephrine ukuba zisebenzise kwimeko ye-anaphylaxis iiyure ezingama-24 emva kwe-Xolair injection.

Ingozi yeCancer

Ngethuba lokuphuhliswa kweekliniki, izinga lomhlaza lalingaphezulu kakhulu kubantu abafumana i-Xolair xa kuthelekiswa nabantu abafumana ii-injection placebo.

Iindidi zeentlobo zamanomhlaza ezibonakalayo kubantu abafumana i-Xolair ziquka umdlavuza webele, umdlavuza wesikhumba, kunye nomhlaza wesifo somhlaza. Akusaziwa ukuba iziphumo ezinokusetyenziswa kwexesha elide le-Xolair zingaba njani kubantu abanomdla wokufumana umdlavuza, njengabantu abadala.

Ngoxa kubonakala ngathi i-Xolair ineempembelelo ezibi kakhulu, kufuneka kukhunjulwe ukuba i-anaphylaxis kunye nomdlavuza wenziwa kuphela kwinani elincinci lezigulane. Akusaziwa ukuba kutheni ezi ziphumo zecala zikhona, nangona uphando luqhubeka ukucacisa isizathu.

Kubalulekile ukuqaphela ukuba i-asthma engalawulwayo ingakhokelela kwiimeko ezinzima, kuquka ukufa.

Kwaye unyango olusetyenziswe ekujongeni ukuhlaselwa yi-asthma, njenge-oral and injection corticosteroids, lunokuluhlu olude lweziphumo ezinokusetyenziswa kwexesha elide. Ngoko ke, kubalulekile ukuxoxa nodokotela wakho ingozi kunye neenzuzo zokuthatha i-Xolair nge-asthma engalawulwayo kwiyeza zempilo zesifo se-asthma.

Xolair ngezinye iimeko zeMpilo

Izifundo ezahlukeneyo zihlolisise inzuzo ye-Xolair ekwenzeni unyango lwe-idiopathic urticaria (i-hives), okanye i-CIU. Uphando olutshanje luhlolisise izigulane ezingama-300 ezine-CIU ezisezibonakaliso nangona zithatha amayeza aqhelekileyo ama-antihistamines.

Izifundo zanikwa i-Xolair kwii-doages ezahlukahlukeneyo kwiiveki ezine. Amaphesenti anesine anesine abantu abafumana i-dose ephezulu yeXolair, kunye neepesenti ezingama-22 zabantu abafumana i-dose-dose ye-Xolair, banesisombululo esipheleleyo semifuba kwinyanga enye ukuya kweyonyango. Iimpawu zandipha kancinci emva kokuba i-Xolair imisiwe, ngoko bekungekho nqondiso yexesha elide luza kuxhamla. Ngo-Matshi 2014, i-FDA ivume ukusetyenziswa kwe-Xolair ye-CIU.